**Index**

**A**
- abuse risk factors, 388–9
- Acceptance and Commitment Therapy (ACT), 69
- acting out, 80
- Acuphase (zuclopenthixol acuphase), 447
- acute hospital psychiatric services, 7
- acute relapse, 383
  - admission refused, 387
  - assessment, 384–5
  - management
    - admission, 385–6
    - after crisis, 386
    - documentation and handover, 386
    - treatment at home, 386
  - preparation, 383–4
- Addenbrookes's Cognitive Examination III (ACE-III)
  - scoring, 516–23
  - test, 524–29
- adjustment disorder, 136
- administrative staff, 11
- Admission to ward, 212–15
- adult safeguarding, 388
- abuse risk factors, 388–9
- assessment, 389–91
  - management
    - documentation and follow-up, 392
    - living in squalor, 393
    - no consent to report, 392–3
    - safeguarding, 391–2
    - self-harm injuries, 391
    - suspected significant injury, 391
    - preparation, 389
- Advance Decision/Advance Directive, 459
- advocacy, 84–6
- advocates, 11
- aggression, 440
  - actual assault, 449
    - arousal signs, 20
  - assessment and verbal de-escalation, 441–2
  - CMHT situations, 448
  - elderly individuals, 447
  - management
    - aftermath, 445–6
    - cause of behaviour, 442
    - oral medication offer, 444
    - rapid tranquillisation (RT), 442–3, 444
    - restraint, 444–5
    - team co-ordination, 444
    - ongoing issues, 449–50
    - preparation, 440–1
    - pressing charges, 442
    - staff injured, 449

---

Edited by Sarah Stringer, Juliet Hurn and Anna M Burnside.  
© 2016 John Wiley & Sons, Ltd. Published 2016 by John Wiley & Sons, Ltd.  
Companion Website: www.psychiatryice.com
antipsychotics (continued)
baseline checks, 488
ongoing monitoring, 489
pregnancy, 186
relative side effect profiles, 492
duration and stopping, 59
efficacy, 58
mode of action, 57–8
monitoring, 59
side effects, 58
time-frame, 58
anti-social personality disorder (ASPD), 480–1
anxiety disorders
differential diagnoses, 142
anxiety exposure graph, 143
aripiprazole
bipolar affective disorder (BPAD), 162
key information, 495, 496
psychosis, 157
rapid tranquilisation (RT), 444
relative side effect profile, 492, 493
Assertive Outreach Team (AOT), 6
assessment, psychiatric, 31
diagnosis, 42–4
formulation, 42–3
history taking
approach, 32–3
content, 33–5
mental state examination (MSE), 36–37
collateral history, 37–8
physical assessment, 37
risk assessment, 38–42
preparation we can leave in place
information gathering, 31
planning, 31–2
asylum seekers, 197
attention deficit hyperactivity disorder (ADHD), 451
atypical depression
differential diagnosis, 136
audits, 116
autistic spectrum disorders, 276–7, 279
B
baby blues, 467
Beck Depression Inventory (BDI), 57
behavioural activation (BA), 73–4
benefits advisors, 11
benign ethnic neutropenia (BEN), 240
benzodiazepines, 63–4, 513
avoid in generalised anxiety disorder (GAD), 145
pregnancy, 186
bio-psycho-social management, 47
bipolar affective disorder (BPAD), 136, 159
assessment, 160–1
baseline checks, 488
bipolar II condition, 163
depression, concurrent, 163
differential diagnosis, 342
hypothyroidism, 163
mania, 341–344
mood stabilisers
ongoing monitoring, 490
key information, 61–63, 502–3
pregnancy, 183–8
rapid cycling disorder, 164
body language, 21–3
borderline personality disorder, see emotionally unstable personality disorder
boundaries, 25–7
breathing exercises, 71
Brief Dynamic Interpersonal Therapy (DIT), 68
Brief Psychiatric Rating Scale (BPRS), 57
bulimia nervosa, 475
burnout, 28–9
C
cannabis, 513
capacity
assessment, 102–3
children and young people, 103
refusal of urgent treatment, 455–60
carbamazepine
bipolar affective disorder (BPAD), 162
key information, 502–3
pregnancy, 186
care coordinator (CC), 10
carers, 93–4
catatonia, 414
assessment, 415–16
comparison with NMS and SS, 410
management, 416–17
physical examination, 416
preparation, 414–15
Child and Adolescent Mental Health Service (CAMHS), 6
child protection concerns, 393
assessment, 396–7
child confides abuse to practitioner, 399
The Children Act (1989), 394
management
discuss with seniors, 397
documentation, 398
follow-up, 398
inform parents of referral to social services, 398
safeguarding referral, 398
social services referral process, 398
preparation, 396
signs of neglect and abuse, 395
vague concerns/suspicions, 399
children
abuse or neglect, 393–99
challenging behaviour, 451
self-harm, 330–35
rapid tranquilisation (RT), 452
legal considerations, 103–4
chlor diazepoxide, 254–5
chlorpromazine
key information, 494
pregnancy, 186
relative side effect profile, 492
chronic depression
differential diagnosis, 136
clitopram
key information, 498
Clinical Institute Withdrawal Assessment of Alcohol scale, revised (CIWA-Ar), 251, 54, 509–10
Clinical Opiate Withdrawal Scale (COWS), 262, 511–12
clinical psychologists, 10
clo mipramine
key information, 499
clonazepam
key information, 504
clozapine, 235–9
benign ethnic neutropenia (BEN), 240
key information, 495
plasma measurements, 238–9
psychosis, 157
relative side effect profile, 492
residual symptoms, 241
smoking, 237
stopping once discharged, 241
tachycardia, 240
neutropenia, 239–40
cognitive analytic therapy (CAT), 69
cognitive behavioural therapy (CBT), 68
cognitive impairment
differential diagnosis, 370
reversible causes, 191
cognitive testing
Mini-Addenbrooke’s Cognitive Examination (M-ACE), 530–31
Montreal Cognitive Assessment (MOCA), 515
community mental health teams (CMHTs), 6
services flowchart, 5
Community Psychiatric Nurses (CPNs), 10
community-based psychiatric services, 6
competence
children and young people, 103–4
complaints, 108
compliments, 107–8
confidentiality, 26–7
driving, 206–7
self-harm in young people, 334
consent
electroconvulsive therapy (ECT), 293
refusal of urgent treatment, 455
contacts, useful, 539–40
counter-transference, 78–9
couples therapy, 70
crisis plan, 315
cultural considerations, 91–3, 95
vague presentation, 370
cyclothymia, 163
differential diagnosis, 342

D
deaths on psychiatric wards, 436
assessment, 436
expected deaths, 438
management
documentation and dissemination, 437–8
immediate, 437
longer-term, 438
working with family, 437
preparation, 436
de-escalation, verbal, 20–1, 22–3, 441–2
delirium, 191, 345
assessment, 346–8
information-gathering, 347
investigations, 486
management
carers, 350–1
follow-up, 351
medical, 349–50
nursing, 349
psychiatric, 350
placement, 351
preparation, 345–6
signs and symptoms, 346
young people, 351
delirium tremens (DTs), 253, 461
assessment, 462
extra delirium tests, 463
GBL/GHB withdrawal, 464–5
management, 463
preparation, 461–2
dementia
assessment, 190–93
dementia screen, 190
management, 193–94
reversible causes of cognitive decline, 191
types, 190
dementia with Lewy bodies (DLB), 190
denial, 80
depot antipsychotics, 58
relative side effects, 493
key information, 496–97
depression, 133–40
assessment, 134–35
bipolar affective disorder (BPAD), concurrent with, 163
cognitive decline, 191
differential diagnoses, 136, 370
emergency department (ED) interviews, 139–40
management
approach and psychoeducation, 137
documentation, 139
medication, 137–8
other interventions, 139
practical advice, 137
psychological interventions, 138–9
risk management, 137
preparation
family interviews, 133–4
information gathering, 133
subtypes, 136
Deprivation of Liberty Safeguards (DoLS), 291, 350
diagnosis, 42–4
dialectical behaviour therapy, 69
diazepam
key information, 504
dictation etiquette, 125–6
discharge from CMHT, 208
CPA, 210–11
discharge from ward, 217–19
planning meeting, 209
preparation, 208–10
discrimination, 89–91, 95
disengagement see non-engagement
dissociative disorders, 375
Dissocial personality disorder, see antisocial personality disorder
do not attend (DNA) patients, 126
double depression
differential diagnosis, 136
doxapin
key information, 499
Driver and Vehicle Licensing Agency (DVLA) regulations, 203
driving and mental health, 203
assessment, 204–5
management
discussion with patient, 206
documentation, 206
immediate risk, 205
ongoing care, 206
preparation, 204
drug-seeking, 361
   assessment, 361–2
   complications/difficulties, 363–4
   management, 362–3
   preparation, 361

drug users, 259–64
   assessment, 260–1
   first episode psychosis (FEP), 152–3, 339
   management, 261–4
   withdrawal symptoms, 262
duloxetine
   key information, 500

E
early intervention (EI)
   Early Intervention Service (EIS), 6
   first episode psychosis (FEP), 147
eating disorders, 470
   anorexia nervosa, 470–76
   assessment, 471–4
   bulimia nervosa, 475
   examination, 470–1
   history, 473
   management
      admit or discharge, 474
      feeding, 475
      handover, 475
      medical treatment, 475
      vitamins, 475
      preparation, 470
      risk assessment, 472
ectasy, 513
ego defence mechanisms, 79–81
electroconvulsive therapy (ECT), 138, 293
   catatonia, 417
   emergency, 297
   given in best interests, 297
   key information for patients, 294
   legal framework, 295
   management, 296–7
   preparation, 293
   emergencies see medical emergencies
   emergency psychiatric care services flowchart, 5
emotionally unstable personality disorder (EUPD), 165, 281
   assessment, 168–70, 282
   differential diagnosis, 342
   difficulties encountered, 167
   discharge refusal, 286
   management
      admissions, 171, 283–5
      discharge, 172, 285
      medications, 171–2
      other considerations, 172
      psychoeducation, 170
      psychological treatments, 172
      team support, 172
      treatment planning, 170–1
   preparation, 167–8, 281–2
   psychological mechanisms, 166–7
   self-discharge, 286
   self-harm on ward, 285–6
   empathy, 32
endocrine dysfunction, 191
erectile dysfunction, 228
escitalopram
   key information, 498
   expectations, 26
extrapyramidal side effects (EPSEs), 226
   management, 232
   compared with Parkinson’s disease (PD), 231
   examination, 229–30

F
factitious disorder, 379
family therapy, 70
fatalities see deaths on psychiatric wards
fever and stiffness see stiff and feverish patients, 408–9
first episode psychosis (FEP), 147, 336
   assessment, 337–8
   drug use (illicit), 152–3, 339
   investigations, 487
   management, 149, 338–9
   immediate risk, 150
   initial plan, 150
   longer-term, 151
   medication, 150
   physical health, 151
   psychoeducation, 150
   psychotherapies, 151
   not first episode, 340
   organic causes, 149
   preparation, 148–9, 336–7
   self-discharge attempted, 340
   first-day orientation, 16–18
   Fitness for interview, 424
   floppy baby syndrome, 186
   fluoxetine
   key information, 498
   pregnancy, 186
   flupentixol
   key information, 496
   relative side effect profile, 493
   fluphenazine
   key information, 496
   relative side effect profile, 493
   fluvoxamine
   key information, 498
   Forensic community team, 6
forensic history, patients with, 179, 269
   assessment, 180, 270–1
   conditional discharge, 180
   custody, patients in, 182
   legal practicalities, 180
   management, 181
      admission, 272
      discharge, 272
      emergency transfer, 273
      immediate, 271–2
      recent arrest, 273
      patient walk-out, 182
      preparation, 179, 269–70
      risk of violence, 182
   Fraser (Gillick) competence, 103
   Forensic sections, 537–8

G
gain, 370–1
gamma-butyrolactone (GBL) withdrawal, 464–5
gamma-hydroxybutyric acid (GHB) withdrawal, 464–5
generalised anxiety disorder (GAD), 141
  assessment, 141–3
  differential diagnosis, 142
  management, 143
  comorbidities, 143
  immediate risk, 143
  medication, 145
  psychoeducation, 144
  psychological help, 145
  self-help, 144
  preparation, 141
  Gestalt psychotherapy, 70
  Gillick competence, 103
  grief
  normal, 136
  pathological, 136

**H**
hallucinogens, 514
haloperidol
  key information, 494, 496
  pregnancy, 186
  rapid tranquilisation (RT), 444
  relative side effect profile, 492, 493
Hamilton Depression Rating Scale (HDRS/HAM-D), 57
handovers, 96, 312–13
hanging, 435
  aftermath, 434
  immediate management, 435
  ongoing management, 434
HARD mnemonic, 408
health promotion, 49
Healthcare assistants (HCAs), 11
heroin, 259–264
history taking
  approach, 32
  empathy with patients, 32
  finding a shared agenda, 32–3
content
  background information, 33
  drug history (DHx), 34
  family history (FHx), 34
  forensic history, 35
  past medical history (PMHx), 34
  past psychiatric history (PPHx), 33–4
  personal history, 34
  pre-morbid personality, 35
  presenting complaint (PC), 33
  presenting complaint, history of (HPC), 33
  social history (FHx), 35
  substance misuse, 34–5
holistic management, 46–7
Home Treatment Team (HTT), 6
home visits, 130
  after appointment, 131–2
  during appointment, 131
  no-answer situations, 132
  preparation, 130–1
Human Rights Act (1998), 104–5
humanistic therapies, 70
humour, 80
hydrocephalus, normal pressure (NPH), 191
hypnotics, 63–4
hypochondriacal disorder, 375
hypothyroidism, 163

**I**
ilness prevention, 49
imipramine
  key information, 499
  pregnancy, 186
inpatient psychiatric services, 7
intellectualisation, 80
interpersonal skills, 13–15
interpreters, working with, 197
investigations
  baseline checks before starting psychotropics, 488
  delirium, 486
  first episode psychosis (FEP), 487
  physical health monitoring, 485
isocarboxazid
  key information, 501

**K**
ketamine, 465, 513
kidney function deterioration, 163

**L**
lamotrigine
  key information, 503
  pregnancy, 186
language barriers
  differential diagnosis, 370
leadership in psychiatry, 115–18
Learning Disabilities (LD) team, 6
learning disability (LD) patients, 274–5, 365
  assessment, 275–7, 366
  autistic spectrum disorders, 277
  behavioural changes, 366
  degrees of LD, 275
  management, 277–8, 367–8
  admission, 277–9
  discharge, 279
  severe cases, 279
  preparation, 365
  rapid tranquilisation, 368
legislation and mental health, 97
  The Children Act (1989), 394
  electroconvulsive therapy (ECT), 295
  Human Rights Act (1998), 104–5
  Mental Capacity Act (2005), 102–3
  Mental Health (Care and Treatment) (Scotland) Act (2003), 532–3
  Mental Health (Northern Ireland) Order (1986), 534–6
  patients with forensic history, 180
  treatment of children and young people, 103–4
letters to medical colleagues, 51
lithium
  baseline checks, 488
  bipolar affective disorder (BPAD), 162
  key information, 61–63, 502
  monitoring, 490
  pregnancy, 186
  renal function deterioration, 163
  side effects, 63
  toxicity, 62, 418
  assessment, 419
  deliberate overdose, 420–1
  key facts, 418
  management, 419–20
  preparation, 418–19
lobepramine
  key information, 499
lorazepam
catatonia, 417
  key information, 504
  rapid tranquilisation (RT), 444

M
Makaton, 367
malingering, 373
  differential diagnosis, 370
management in psychiatry, 115–18
  general principles, 46–7
  holistic management, 46–7
  recovery approach, 45–6
  shared plans, 46
mania, 341
  admission/discharge, 344
  assessment, 341–3
  differential diagnosis, 342
  management, 343
  mixed affective state, 344
  preparation, 341
Maslow’s Hierarchy of Needs, 84
maternity blues, 467
medical emergencies, 52, 401
  assessment, 402
catatonia, 414
  assessment, 415–16
  management, 416–17
  physical examination, 416
  preparation, 414–15
hanging, 435
  aftermath, 434
  immediate management, 435
  ongoing management, 434
  simulated, 435
lithium toxicity, 418
  assessment, 419
  deliberate overdose, 420–1
  key facts, 418
  management, 419–20
  preparation, 418–19
management of medical emergencies, 403
opiate overdose, 405
  assessment and management, 405–7
  preparation, 405
preparation, 401
refusal of urgent treatment, 455
  already inpatient, 459
  assessment, 456–8
  management, 458–9
  patient has Advance Decision/Advance Directive, 459
  preparation, 455–6
refusal to comply with care plan, 404
stiff and feverish patients, 408
  assessment, 409–11
  causes, 409
  comparison with lethal catatonia, 410
  management, 411–12
  preparation, 408–9
medically unexplained symptoms, 374
  assessment, 375–7
  baseline checks, 488
  ongoing monitoring, 489
examples, 375
factitious disorder, 379
malingering disorder, 379
malingering possibility, 378
management
  family involvement, 378
  handover, 378
  psychoeducation, 377
  realistic hope, 377–8
  treatment options, 378
refusal of help, 378
medications, 53
  antipsychotics
    key information, 57–59, 494, 496–7
    relative side effect profiles, 492
discussing with patients, 55
  introducing medication, 55–6
  providing information and choices, 56
  team approach, 56
medicines management, 53
  administration, 55
  discontinuing, 55
  dispensing, 55
  prescribing, 54
  reviewing, 55
  selecting, 54
mood stabilisers, 61–63, 502–3
  non-SSRI antidepressants, 499–501
  antidepressants, 59–61, 488
  mood stabilisers, 61–3, 488, 490
PRN medications, 63–4, 504
sedatives, 63–64, 504
selective serotonin reuptake inhibitors (SSRIs), 498
melatonergic antidepressants, 500
Mental Capacity Act (2005), 102
  assessing capacity, 102–3, 455–60
  Deprivation of Liberty Safeguards (DoLS), 103
Mental Health (Care and Treatment) (Scotland) Act (2003), 532–3
Mental Health (Northern Ireland) Order (1986), 534–6
Mental Health Act (1983, amended 2007), 97, 537–8
  amendments, 98
  common civil sections, 99–100
  consent to treatment, 101–2
  forensic sections, 537–38
  guiding principles, 98
  responsibilities, 98–101
Mental Health of Older Adults (MHOA) team, 6
  referral criteria, 290
mental health services overview, 5–8
  acute hospital services, 7
  community services, 6
  flowchart, 5
  inpatient services, 7
  recent provision trends, 8
mental state examination (MSE), 36
  appearance and behaviour (A & B), 36
  cognition (C), 37
  insight (I), 37
  mood (M), 36
  perception (P), 36
  speech (S), 36
  thought (T), 36
mental toll of psychiatric work, 28–30
Mentalisation-Based Therapy (MBT), 69–70
metabolic syndrome, 49, 231, 233, 485
methadone, 261–2
midazolam
  rapid tranquilisation (RT), 444
mindfulness, 68
  obsessive compulsive disorder (OCD), 355
Mini-Addenbrooke's Cognitive Examination (M-ACE), 530–31
mirtazapine
  key information, 499
mixed affective state, 344
moclobemide
  key information, 501
monitoring
  antidepressants, 488
  antipsychotics, 488, 489
  mood stabilisers, 488, 490
  physical health, 485
  rapid tranquilisation (RT), 491
monoamine oxidase inhibitors (MAOIs), 501
Montgomery–Asberg Depression Scale (MADRS), 57
Montreal Cognitive Assessment (MOCA), 515
mood stabilisers, 61
  duration and stopping, 62
  key information, 502–3
  lithium, 61–63, 162, 186, 488–90, 502
  mode of action, 61
  monitoring, 62, 488, 490
  pregnancy, 186
  recovery likelihood, 61
  side effects, 61–2, 63
  sodium valproate, 61–63, 488–90, 502
  time-frame, 61
motivational interviewing (MI), 74–6
Munchausen syndrome, 379
N
Neuroleptic Malignant Syndrome (NMS), 408
  assessment, 409–11
  causes, 409
  comparison with lethal catatonia, 410
  management, 411–12
  preparation, 408–9
neurolinguistic programming, 70
nonadrenergic and specific serotonergic antidepressants (NASSAs), 499
non-confrontational engagement, 22
non-engagement (disengagement), 174
management
  initial, 176
  longer-term, 176–8
  preparation, 174
  reasons, 175
  solutions, 177
normal pressure hydrocephalus (NPH), 191
nortriptyline
  pregnancy, 186
olanzapine
  bipolar affective disorder (BPAD), 162
  key information, 495, 497
  pregnancy, 186
  rapid tranquilisation (RT), 444
  relative side effect profile, 492, 493
older adults, 189, 287
  assessment, 190–3, 288
  dementia types, 190
  informal admission, 291
  management
    admission, 289–90
    anti-dementia medication, 193–4
    discharge, 291
    immediate risk, 193
    physical health, 193
    psychoeducation and advice, 193
    referral, 193
    treatment, 193
  preparation, 189–90, 287
  rapid tranquilisation (RT), 447
on-call duty
  first shift, 307
  discharges, 315–16
  handovers, 312–13
  Mental Health Act (MHA), 311–12
  placement specifics, 311
  preparation, 307–8
  prioritizing, 313
  team working, 309–10
  transfers, 313–15
operant conditioning, 77
opiates, 259–64
  opiate overdose, 405
  assessment and management, 405–7
  preparation, 405
oppositional defiant disorder, 451
organic disease
  differential diagnosis, 370, 486, 487
outpatient clinics, 123
  after clinic, 125–6
  do not attend (DNA) patients, 126
  during appointments
    efficiency, 124–5
    note taking, 124
    time management, 124
  preparation
    administrator, 123
    clinic preparation, 124
    communication within team, 124
    consultant, 123
  oxazepam, 255
  key information, 504
P
Pabrinex, 255–56
paliperidone
  key information, 497
  relative side effect profile, 493
panic attacks, 357
management, 358
  attack during assessment, 359–60
  first attack, 359
panic attacks (continued)
treatment, 359
preparation, 357
panic disorder
differential diagnosis, 142
parental responsibility (PR), 104
Parkinson's disease (PD)
compared with extrapyramidal side effects (EPSEs), 231
paroxetine
key information, 498
pregnancy, 186
passive aggression, 80
persistent somatoform pain disorder, 375
personal development plan (PDP), 111
personality disorders
anti-social personality disorder (ASPD), 480–1
emotionally unstable personality disorder (EUPD), 165–73, 281–6
person-centred counselling, 70
puerperal psychosis, 466
assessment, 467–8
management, 468–9
postpartum differentials, 467
preparation, 466
pharmacists, 10
phenelzine
key information, 501
phobias, specific
differential diagnosis, 142
physical assessment of patients, 37
physical healthcare, 48
barriers, 48
community-based, 50–1
health promotion and illness prevention, 49
liaising with other health care professionals, 51
medical emergencies, 52
monitoring, 485
ward-based, 50
pipotiazine
key information, 496
relative side effect profile, 493
planning for assessments, 31–2
police
interviews, fitness for, 424
involvement in aggression, 442, 445, 447, 480–81
involvement in alleged sexual assault, 425
pressing charges, 442
s136, 298
wellfare check, 245
Positive and Negative Syndrome Scale (PANSS), 57
post-natal depression (PND), 467
post-traumatic stress disorder (PTSD), 196
differential diagnosis, 142
pregnancy and mental health, 183, 265
antenatal care refusal, 268
assessment, 184, 265–6
management
admission, 267
after delivery, 187–8
discharge, 267–8
feedback and planning, 185
immediate, 266–7
medication advice, 185
once pregnant, 187
other steps, 187
perinatal service referral, 185
psychoeducation, 184–5
medication, 186
preparation, 183–4, 265
prescribing principles, 185, 187
privacy, 26–7
progressive muscle relaxation, 71–2
projection, 80
promethazine, 63–4
key information, 504
pregnancy, 186
rapid tranquilisation (RT), 444
psychiatric assessment see assessment, psychiatric
Psychiatric Intensive Care Unit (PICU), 7
seclusion/supervised confinement, 246
psychoanalyst, 7
role of, 13–15
psychoanalytic psychotherapy, 68
psychodynamic approaches to therapy, 78
ego defence mechanisms, 79–81
transference and counter-transference, 78–9
psychodynamic psychotherapy, 68
psychological interventions, 65
brief interventions, 70
behavioural activation (BA), 73–4
motivational interviewing (MI), 74–6
relaxation techniques, 71–6
sleep hygiene, 72
SMART goals, 72–3
exclusion criteria for therapy, 71
interaction dynamics, 76
functional approach, 76–8
psychodynamic approaches, 78–81
psychoeducation, 65–6
psychotherapies, 66–7
suitability for therapy, 67
summary, 68–70
psychosis, 147, 154, 336
see also first episode psychosis (FEP); puerperal psychosis
assessment, 155–6
differential diagnosis, 370
formulation, 43
management
comorbidities, 156
immediate risks, 156
longer-term plans, 158
medication, 157
psychoeducation, 156
psychosocial interventions, 157
recovery approach, 157
preparation, 154–5
psychotropics
antidepressants
baseline checks, 488
duration and stopping, 60–1
efficacy, 60
mode of action, 59
monitoring, 60
side effects, 60
time-frame, 60
antipsychotics
baseline checks, 488
duration and stopping, 59
efficacy, 58
mode of action, 57–8
monitoring, 59, 489
side effects, 58
time-frame, 58
baseline checks, 488
mood stabilisers, 61
baseline checks, 488
duration and stopping, 62
mode of action, 61
monitoring, 62, 488–490, 502
recovery likelihood, 61
side effects, 61–2
time-frame, 61
puerperal psychosis, 466
assessment, 467–8
management, 468–9
postpartum differentials, 467
preparation, 466
quality of care, 115–16
questions from patients, answering, 26–7
quetiapine
bipolar affective disorder (BPAD), 162
key information, 495
pregnancy, 186
relative side effect profile, 492
rapid cycling bipolar affective disorder, 164
rapid tranquillisation (RT), 442–3
cautions and contraindications, 490
children, 452
elderly patients, 447
factors affecting choice, 443
monitoring, 491
options for fit adults, 444
people with learning disabilities, 447
protocol, 443
rating scales, 57
rationalisation, 80
recurrent depressive disorder
differential diagnosis, 136
refugees, 197
refusal of urgent treatment, 455
already inpatient, 459
assessment, 102–3, 456–8
management, 458–9
patient has Advance Decision/Advance Directive, 459
preparation, 455–6
Registered Mental Health Nurse (RMN), 10
regression, 80
relaxation techniques, 71
breathing exercises, 71
progressive muscle relaxation, 71–2
reliability, 26
renal function deterioration, 163
research in psychiatry, 117–19
restraint of patients, 444–5
risk assessment, 38
depression, 135
documentation, 41–2
eating disorders, 472
general principles, 38
management of risk, 41
methods, 38–9
protective factors, 39
risk factors, 39
risk formulation, 41
suicide/self-harm, 39–40, 318–23
violence, 40–1, 477–79
risperidone
bipolar affective disorder (BPAD), 162
key information, 495, 497
pregnancy, 186
rapid tranquillisation (RT), 444
relative side effect profile, 492, 493
Rogerian counselling, 70
safety considerations, 19–20
approach, 21–3
armed individuals, 447
debriefing after incidents, 23
home visits, 130
patients with forensic history, 182
risk assessment, 38
documentation, 41–2
general principles, 38
management of risk, 41
methods, 38–9
protective factors, 39
risk factors, 39
risk formulation, 41
suicide/self-harm, 39–40, 318–23
violence, 40–1, 477–79
threats of violence, 477
secrecy, 26
Section 5(2) detention, 244–5
Section 136, 99, 298
assessment, 300
key facts, 299
management, 301
preparation, 298
ward personnel, 299
sedatives
key information, 63–64, 504
pregnancy, 186
selective serotonin reuptake inhibitors (SSRIs)
baseline checks, 488
depression, 138
generalised anxiety disorder (GAD), 145
key information, 498
side effects, 60
self-discharge, 242–4
self-harm, 285–6, 318, 391
admission/discharge factors, 326
assessment, 39–40, 319–23
avoiding being fooled, 323
complications/difficulties, 327–9
management, 323–6
minimization of harm, 325
preparation, 318–19
presentation suicide risk factors, 322
risk assessment, 39
risk factors, 321
suicide risk factors, 322
ward-based, 428
assessment, 429
fatalities, 431
management, 430–1
overdose possibility, 431
preparation, 428
self-harm in young people, 330
assessment, 331–2
confidentiality, 334
management, 332–4
preparation, 330
serious incidents (SIs), 108–9
serotonin and noradrenaline reuptake inhibitors (SNRIs), 499–500
serotonin antagonists and reuptake inhibitors (SARIs), 500
Serotonin Syndrome (SS), 408
assessment, 409–11
causes, 409
comparison with lethal catatonia, 410
management, 411–12
preparation, 408–9
sertraline
key information, 498
pregnancy, 186
Severity of Alcohol Dependence Questionnaire (SADQ), 508
sex offender assessment, 425–7
sexual assault, alleged, 422
assessment, 423–4
fitness for police interview, 424
management, 424–5
preparation, 422–3
Sexual Assault Referral Centres (SARCs), 423
staff member is accused, 425
staff member is victim, 425
side effect management, 225, 234
assessment, 226–7
common side effects, 228–31
management options, 232–3
investigations, 231
preparation, 226
side effects
antidepressants, 60
antipsychotics, 58, 492–93
lithium, 63
mood stabilisers, 61–2, 63
selective serotonin reuptake inhibitors (SSRIs), 60
valproate, 63
skills needed for psychiatry, 13–15
sleep hygiene, 72
SMART goals, 72–3
social interventions, 83
advocacy, 84–6, 95
benefits, 89, 95
cultural issues, 91–3, 95
discrimination, 89–91, 95
employment, 87–9, 95
friends and family, 93–4
general points, 83–4
housing and support options, 86–7, 95
social management options, 84
stigma, 89–91, 95
social phobia
differential diagnosis, 142
social presentations, 369
assessment, 371–2
demanding patients, 373
malingering, 373
management, 372
preparation, 369
vague presentation, 370
social workers, 10
sodium valproate see valproate/sodium valproate
solvent abuse, 514
somatisation disorder, 375
somatoform autonomic dysfunction, 375
space occupying lesion (SOL), 191
spiked drinks, 465
splitting, 80
St John’s wort, 138
stiff and feverish patients, 408
assessment, 409–11
causes, 409
comparison with lethal catatonia, 410
management, 411–12
preparation, 408–9
stigma of mental illness, 89–91, 95
stimulants, 513
stress, 28–30
stress reactions
differential diagnosis, 370
Substance Misuse Service, 6
substance misuse/dependency
alcohol, 251–4
delirium tremens (DTs), 461–5
management, 254–8
presentations, 253
drug-seeking behaviour, 361
Clinical Opiate Withdrawal Scale (COWS), 511–12
drug-induced psychosis, 152–3, 339
history taking, 34–5
illicit drug summary, 513–14
illicit drugs, 259–60
assessment, 260–1
management, 261–4
withdrawal symptoms, 262
suicide
historic and demographic risk factors, 322
presentation risk factors, 322
risk assessment, 39, 318–23
sulpiride
key information, 494
relative side effect profile, 492
supervision, 110–11
support workers, 11
T
tasers, 299
teaching, 113–14
team personnel, 9–11
tear gas, 299
teratogenic substances, 61
thiamine deficiency, 255–6, 463
time management, 27–8
touch, appropriate, 26
transfers, 313–15
checklists, 314
transthyretin
key information, 501
TRAPPED mnemonic, 34–5
trauma, 196
  assessment, 197–200
  management, 200–1
  preparation, 196–7
trazadone, 500
treatment-resistant depression
  differential diagnosis, 136
triage for mental health, 7
tribunals, 303
  after hearing, 306
  during hearing, 304–5
  preparation, 304
  role, 303–4
tricyclic antidepressants
  key information, 499
trifluoperazine
  key information, 494
  relative side effect profile, 492
  pregnancy, 186
trimipramine
  key information, 499
U
urine drug screen (UDS), 261
unexplained symptoms see medically unexplained symptoms
useful contacts, 539–40
V
vague presentations, 370
valproate/sodium valproate
  baseline checks, 488
  bipolar affective disorder (BPAD), 162
  key information, 61–3, 502
  ongoing monitoring, 490
  pregnancy, 186
  side effects, 63
vascular dementia (VD), 190
venlafaxine
  key information, 500
verbal de-escalation, 20–1, 22–3, 441–2
violence, or threat of, 19–20, 440, 477
  actual assault, 449
  anti-social personality disorder (ASPD), 480–1
  approach, 21–3
  armed individuals, 447
  assessment, 40–1, 478–9
  assessment and verbal de-escalation, 441–2
  CMHT situations, 448
  debriefing, 23
  elderly individuals, 447
  management, 480
  aftermath, 445–6
  cause of behaviour, 442
  oral medication offer, 444
  rapid tranquilisation (RT), 442–3, 444
  restraint, 444–5
  team co-ordination, 444
ongoing issues, 449–50
patients with forensic history, 182, 269
preparation, 440–1, 477
pressing charges, 442
reasons for, 24
risk assessment, 40–1, 477–79
risk factors, 478
staff injured, 449
verbal de-escalation, 20–1, 22–3
ward situations, 448
vitamin B_{12} deficiency, 191
vocational workers, 11
W
ward-based psychiatric care, 7
  admission to discharge pathway, 212
  admission plan, 214–15
  admissions clerking, 212
  assessment, 213–14
  assessment needed but refused, 220
  discharge, 217–19
  incomplete clerking, 220
  preparation, 213
  readmissions, 219
  reluctance to be discharged, 220
  sudden discharge, 220
  treatment phase, 215–17
  services flowchart, 5
  ward rounds, 221
  after round, 223
  aims, 221
  preparation, 222
  procedure, 222–3
Wernicke’s encephalopathy (WE), 253, 255
Wernicke–Korsakoff syndrome, 191
Whale music, expensive, 67
WPBAs, 111–12
Y
Young Mania Rating Scale (YMRS), 57
young people
  delirium, 351
  legal considerations, 103–4
  self-harm, 330
  assessment, 331–2
  confidentiality, 334
  management, 332–4
  preparation, 330
Z
zopiclone, 150
  key information, 504
zuclopenthixol acetate (Acuphase), 448
  key information, 494
  relative side effect profile, 492, 493
zuclopenthixol decanoate (Clopixol)
  key information, 496